BioXcel Therapeutics Reports Q4 and Full-Year Results

BioXcel Therapeutics has released its financial results for the fourth quarter and the entire year. The company's update also includes information regarding regulatory submissions, specifically an sNDA seeking approval for IGALMI® in an at-home setting for bipolar disorder agitation. This development signifies progress in their drug development pipeline and potential market expansion. Investors are likely focused on the commercial prospects of IGALMI® and the company's overall financial health.